DDInter298 DDInter495
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Carboplatin {u} (Compound) treats {v} (Disease) brain cancer
brain cancer {u} (Disease) is palliated by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Delafloxacin
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Delafloxacin
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Metformin
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Carboplatin {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Cisplatin
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Aluminum hydroxide
Aluminum hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delafloxacin
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Carboplatin (Compound) treats brain cancer (Disease) and brain cancer (Disease) is palliated by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Delafloxacin
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Delafloxacin
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Metformin (Compound) and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Carboplatin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Cisplatin (Compound) and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Aluminum hydroxide (Compound) and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin